XCancer
Point Biopharma

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)

Description:

The purpose of this study is to evaluate the efficacy and safety of [Lu-177]-PNT2002 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with androgen receptor axis-targeted therapy (ARAT).

Sponsor:

Point Biopharma

Phase:

Phase 3

Government Study Link:

NCT04647526 - Click here to see study on

ClinicalTrials.gov

Isotope(s):
Target(s):

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

Loading...